MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Ironwood Pharmaceuticals Inc

Ouvert

SecteurSoins de santé

0.86 3.61

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.8

Max

0.89

Chiffres clés

By Trading Economics

Revenu

-1.4M

2.3M

Ventes

-1M

91M

P/E

Moyenne du Secteur

70.49

57.333

BPA

0.02

Marge bénéficiaire

2.492

Employés

253

EBITDA

6.1M

33M

Dividendes

By Dow Jones

Prochains Résultats

8 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-249M

118M

Ouverture précédente

-2.75

Clôture précédente

0.86

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Ironwood Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 avr. 2025, 14:26 UTC

Principaux Mouvements du Marché

Ironwood Pharma Shares Fall on Word of Confirmatory Phase 3 Apraglutide Trial

Comparaison

Variation de prix

Ironwood Pharmaceuticals Inc prévision

Note du Consensus

By TipRanks

Neutre

6 ratings

0

Achat

6

Maintien

0

Vente

Score Technique

By Trading Central

0.7222 / 0.9055Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.